Key Considerations for Adverse Event Management in mRCC: TKI Monotherapy vs ICI + TKI Combinations
Panelists discuss how the management of adverse events differs between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor plus TKI (ICI+TKI) combinations, including any notable differences in adverse effect profiles among various ICI plus TKI regimens used in treating metastatic renal cell carcinoma.
EP: 1.Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making
EP: 2.Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC
EP: 3.Navigating ICI Plus TKI Combinations for First-Line mRCC: Key Factors in Decision-Making
EP: 4.Key Disease Characteristics Influencing the Choice Between ICI + TKI and ICI + ICI Regimens in mRCC
EP: 5.Key Considerations for Adverse Event Management in mRCC: TKI Monotherapy vs ICI + TKI Combinations
EP: 6.Impact of Adjuvant Immunotherapy on First-Line Treatment Decisions for Newly Diagnosed mRCC
- In your experience, how does the management of adverse events differ between tyrosine kinase inhibitor (TKI) monotherapy and immune checkpoint inhibitor (ICI) plus TKI combinations?
- Are there any notable differences between the various ICI plus TKI regimens?
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
GU Oncology Peers Explore Early Therapy Approaches in Low-Volume mRCC
September 19th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on treating patients with indolent or low-volume favorable-risk metastatic clear cell renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
